Radio and PodcastLive Radio & PodcastsScience & Medicine
144 - Aimovig for migraine; lofexidine for opioid withdrawal; 3-D printing 510(k) clearance; Gottleib statement on branded drug companies blocking generics
144 - Aimovig for migraine; lofexidine for opioid withdrawal; 3-D printing 510(k) clearance; Gottleib statement on branded drug companies blocking generics is an episode from New FDA Approvals. This science & medicine ep...
About This Episode
144 - Aimovig for migraine; lofexidine for opioid withdrawal; 3-D printing 510(k) clearance; Gottleib statement on branded drug companies blocking generics is an episode from New FDA Approvals. This science & medicine episode is made for li...
Podcast
This episode belongs to New FDA Approvals.
Listen Online
Use the player on this page to stream the episode online.
Episode Details
Published May 18, 2018, 10:24 long, audio available.
Related Episodes
Continue listening to more episodes from New FDA Approvals.
Questions About This Episode
What is 144 - Aimovig for migraine; lofexidine for opioid withdrawal; 3-D printing 510(k) clearance; Gottleib statement on branded drug companies blocking generics about?
144 - Aimovig for migraine; lofexidine for opioid withdrawal; 3-D printing 510(k) clearance; Gottleib statement on branded drug companies blocking generics is a podcast episode from New FDA Approvals. You can listen online and use the related episode section to continue with more content from the same show.
Where can I listen to 144 - Aimovig for migraine; lofexidine for opioid withdrawal; 3-D printing 510(k) clearance; Gottleib statement on branded drug companies blocking generics?
You can listen to 144 - Aimovig for migraine; lofexidine for opioid withdrawal; 3-D printing 510(k) clearance; Gottleib statement on branded drug companies blocking generics online on Radio and Podcast. Open the player on this page to stream the available audio.
Which podcast is 144 - Aimovig for migraine; lofexidine for opioid withdrawal; 3-D printing 510(k) clearance; Gottleib statement on branded drug companies blocking generics from?
144 - Aimovig for migraine; lofexidine for opioid withdrawal; 3-D printing 510(k) clearance; Gottleib statement on branded drug companies blocking generics is an episode from New FDA Approvals.
How long is this episode?
This episode is 10:24 long.
When was this episode published?
This episode was published on May 18, 2018.
Can I save 144 - Aimovig for migraine; lofexidine for opioid withdrawal; 3-D printing 510(k) clearance; Gottleib statement on branded drug companies blocking generics for later?
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Are there related episodes from New FDA Approvals?
Yes. This page shows related episodes from New FDA Approvals when more episodes are available from the podcast feed.
Quick Answers About This Episode
Where can I listen to 144 - Aimovig for migraine; lofexidine for opioid withdrawal; 3-D printing 510(k) clearance; Gottleib statement on branded drug companies blocking generics?
You can listen to 144 - Aimovig for migraine; lofexidine for opioid withdrawal; 3-D printing 510(k) clearance; Gottleib statement on branded drug companies blocking generics on this page when the episode audio is available from the podcast feed.
Which podcast is this episode from?
144 - Aimovig for migraine; lofexidine for opioid withdrawal; 3-D printing 510(k) clearance; Gottleib statement on branded drug companies blocking generics is from New FDA Approvals.
What are the episode details?
Published May 18, 2018 and 10:24 long